Theradaptive, which has received three breakthrough device designations for its regenerative implants, said it received $7.4m from the US Department of Defense (DoD), bringing its total funding from the DoD to $33m. The company previously received $26m from he DoD in series A funding.
The Frederick, MD and Boston-based start-up said on 12 September the funding will be used to prepare for first human clinical trials of its therapeutic delivery
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?